Radioimmunotherapy
Radioimmunotherapy | |
---|---|
Other names | RIT |
ICD-9-CM | 92.28 |
MeSH | D016499 |
Radioimmunotherapy (RIT) uses an
cancer therapy, an antibody with specificity for a tumor-associated antigen is used to deliver a lethal dose of radiation to the tumor cells. The ability for the antibody to specifically bind to a tumor-associated antigen increases the dose delivered to the tumor cells while decreasing the dose to normal tissues. By its nature, RIT requires a tumor cell to express an antigen that is unique to the neoplasm
or is not accessible in normal cells.
History of available agents
Name | Description | FDA status |
EMA status |
Ibritumomab tiuxetan (Zevalin) | monoclonal antibody anti-CD20 conjugated to a molecule that chelates Yttrium-90. | Approved (2002)[2][3] | Authorised (2004)[4] |
Iodine (131I) tositumomab (Bexxar) | links a molecule containing Iodine-131 to an anti-CD20 monoclonal antibody | Approved (2003)[5] Withdrawn (2014)[6] |
Orphan drug (2003) Withdrawn (2015)[7] |
Lutetium (177Lu) lilotomab satetraxetan (Betalutin) | combination of lutetium-177 and an anti-CD37 monoclonal antibody |
Fast track (2020)[8] | Orphan drug (2020)[9] |
131I tositumomab and 90Y ibritumomab tiuxetan were the first agents of radioimmunotherapy, and they were approved for the treatment of refractory
non-Hodgkin's lymphoma. This means they are used in patients whose lymphoma is refractory to conventional chemotherapy and the monoclonal antibody rituximab
.
Agents in clinical development
A set of radioimmunotherapy drugs that rely upon an
phase II clinical trials for the treatment of acute myeloid leukemia have been carried out using alpha-emitting RITs.[10][11]
90Y-FF-21101 is a monoclonal antibody against
phase I clinical trial began in 2015.[14]
Other applications (non-approved indications)
Other types of cancer for which RIT has therapeutic potential include
neoplastic meningitis,[17] leukemia,[18] high-grade brain glioma,[19] and metastatic colorectal cancer.[20]
Components of the extracellular matrix and the tumor microenvironment can also be targeted by radioimmunotherapy, such as Netrin-1 [21] (an axon guidance protein) and FAP (a marker for cancer associated fibroblasts).[22]
References
- S2CID 22166498.
- ^ FIbritumomab Tiuxetan (Zevalin™) Radioimmunotherapy of Non-Hodgkin’s Lymphoma
- ^ Rao AV, Akabani G, Rizzieri DA. Radioimmunotherapy for Non-Hodgkin's Lymphoma. Clin Med Res. 2005 Aug;3(3):157-65.
- ^ "Zevalin". European Medicines Agency. Retrieved 8 November 2020.
- ^ Tositumomab and Iodine I 131 Tositumomab – Product Approval Information – Licensing Action
- ^ "Why Good Drugs Sometimes Fail: The Bexxar Story". 2013-08-26.
- ^ "EU/3/03/136". European Medicines Agency. Retrieved 8 November 2020.
- ^ "FDA grants fast track status to Betalutin for marginal zone lymphoma". Healio. 29 June 2020.
- ^ "EU/3/20/2280". European Medicines Agency. Retrieved 8 November 2020.
- PMID 26897718.
- PMID 31451417.
- PMID 32816889.
- PMID 31717302.
- ^ A Phase 1 Dose-escalation Study of Radio- Labeled Antibody, FF-21101(90Y) for the Treatment of Advanced Cancer
- ^ Smith-Jones PM. Radioimmunotherapy of prostate cancer. Q J Nucl Med Mol Imaging. 2004 Dec;48(4):297-304.
- ^ Dadachova E, Nosanchuk JD, Shi L, Schweitzer AD, Frenkel A, Nosanchuk JS, and Casadevall A. Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a monoclonal antibody to melanin. Proc Natl Acad Sci USA 2004;101: 14865-70.
- ^ a b Zalutsky MR, Pozzi OR. Radioimmunotherapy with alpha-particle emitting radionuclides. Q J Nucl Med Mol Imaging. 2004 Dec;48(4):289-96.
- ^ Burke JM, Jurcic JG. Radioimmunotherapy of leukemia. Adv Pharmacol. 2004;51:185-208.
- ^ Quang TS, Brady LW. Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):972-5.
- ^ Wong JY, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, Yamauchi DM, Wilczynski S, Ikle DN, Wu AM, Yazaki PJ, Shively JE, Doroshow JH, Raubitschek AA. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5842-52
- ^ Kryza D, Wischhusen J, Richaud M, Hervieu M, Sidi Boumedine J, Delcros JG, Besse S, Baudier T, Laval PA, Breusa S, Boutault E, Clermidy H, Rama N, Ducarouge B, Devouassoux-Shisheboran M, Chezal JM, Giraudet AL, Walter T, Mehlen P, Sarrut D, Gibert B.From netrin-1-targeted SPECT/CT to internal radiotherapy for management of advanced solid tumors. EMBO Mol Med. 2023 Apr 11;15(4):e16732. doi: 10.15252/emmm.202216732. Epub 2023 Mar 6. PMID: 36876343
- ^ Marko Magdi Abdou Sidrak, Maria Silvia De Feo, Ferdinando Corica, Joana Gorica, Miriam Conte, Luca Filippi, Orazio Schillaci, Giuseppe De Vincentis, and Viviana Frantellizzi1,Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics—Where We Are at and Where We Are Heading: A Systematic Review Int J Mol Sci. 2023 Feb; 24(4): 3863. Published online 2023 Feb 15. doi: 10.3390/ijms24043863
External links
- Radioimmunotherapy at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
- Radioimmunotherapy.org